Healthcare & pharmaceutical equity investment research - Page 2

Healthcare Insights

OSE Immunotherapeutics (PAR: OSE) – AbbVie partnership amendment >

Arron Aatkar, PhD | Healthcare | Comment | 3 days ago

OSE Immunotherapeutics (PAR: OSE) – AbbVie partnership amendment >

Arron Aatkar, PhD | Healthcare | Comment | 3 days ago

SEE ALL COMMENTARY >

Market cap

Date (published)

thematic

Healthcare

11.11.24

Healthcare-focused trusts: A sector on the mend

thematic

Healthcare

22.09.25

The CNS renaissance: Innovations are reshaping neurological therapies

Healthcare

thematic

11.11.25

Edison explains: Investing in health stocks – how policy clarity is opening doors

Latest

Healthcare | Flash

10.12.25

Mendus — ASH 2025 update supports renewed strategy

Healthcare | Flash

09.12.25

OSE Immunotherapeutics — Strategic plan presented for 2026–2028

Healthcare | Flash

09.12.25

Immix Biopharma — Promising NEXICART-2 data; runway extended

Healthcare | Flash

09.12.25

Oryzon Genomics — ASH 2025: Promising iadademstat updates

insight

Healthcare

25.05.23

An update on OpGen: Deals, expansion and revenues

insight

Healthcare

18.05.23

Volition: Views from the sharp end

insight

Healthcare

18.05.23

Incannex Healthcare: Data opens path to treat anxiety

insight

Healthcare

09.02.23

February 2023 Edition of Edison Healthcare Insight

insight

Healthcare

30.01.23

VolitionRx: Commercializing the Nu.Q Vet Cancer Test: Webinar

insight

Healthcare

20.12.22

Encouraging top-line data from Unyvero urinary tract infection (UTI) panel

Equities

Region

Market cap

Immix Biopharma (IMMX)

Latest price

USD6.73

▾ 0.13 (1.97)

As at 10/12/2025

Market capitalisation: USD222m

View equity

Flash

Healthcare

09.12.25

Immix Biopharma — Promising NEXICART-2 data; runway extended

Update

Healthcare

13.11.25

Immix Biopharma — Primed to pick up the pace in ALA

Flash

Healthcare

19.09.25

Immix Biopharma — NEXICART-2 enrolment progressing well

See more
content on

Immix Biopharma

IRLAB Therapeutics (IRLAB-A)

Latest price

SEK1.98

▾ −0.04 (−1.98)

As at 10/12/2025

Market capitalisation: SEK172m

View equity

Flash

Healthcare

27.03.25

IRLAB Therapeutics — Next steps laid out for IRL757

Update

Healthcare

06.03.25

IRLAB Therapeutics — Pirepemat stumbles in Phase IIb study

Flash

Healthcare

20.02.25

IRLAB Therapeutics — EMA alignment on mesdopetam Phase III plans

See more
content on

IRLAB Therapeutics

KALA BIO (KALA)

Latest price

USD0.77

▾ −0.02 (−2.04)

As at 10/12/2025

Market capitalisation: USD8m

View equity

LTR Pharma (LTP)

Latest price

AUD0.48

▾ 0.02 (3.23)

As at 10/12/2025

Market capitalisation: AUD55m

View equity

Quickview

Healthcare

23.10.25

LTR Pharma — Sizable upside potential for intranasal delivery

See more
content on

LTR Pharma

Medigene (MDG1)

Latest price

EUR0.13

▾ −0.05 (−27.57)

As at 10/12/2025

Market capitalisation: —

View equity

Mendus (IMMU)

Latest price

SEK5.00

▾ −0.15 (−2.91)

As at 10/12/2025

Market capitalisation: SEK314m

View equity

Flash

Healthcare

10.12.25

Mendus — ASH 2025 update supports renewed strategy

Flash

Healthcare

27.11.25

Mendus — Ovarian cancer: another shot at goal

Outlook

Healthcare

20.11.25

Mendus — New strategy broadens vididencel potential

See more
content on

Mendus

MindMaze Therapeutics (RLF)

Latest price

CHF2.81

▾ −0.09 (−3.10)

As at 10/12/2025

Market capitalisation: CHF41m

View equity

Newron Pharmaceuticals (NWRN)

Latest price

CHF19.88

▾ −0.32 (−1.58)

As at 10/12/2025

Market capitalisation: CHF361m

View equity

Flash

Healthcare

08.12.25

Newron Pharmaceuticals — Phase III ENIGMA-TRS 2 trial underway

Update

Healthcare

18.09.25

Newron Pharmaceuticals — H125 results reflect evenamide progress

Flash

Healthcare

12.08.25

Newron Pharmaceuticals — ENIGMA-TRS 1 commences enrolment

See more
content on

Newron Pharmaceuticals

Nykode Therapeutics (NYKD)

Latest price

NOK2.43

▾ −0.12 (−4.78)

As at 10/12/2025

Market capitalisation: NOK834m

View equity

QuickView

Healthcare

09.12.24

Nykode Therapeutics — Repositioned to streamline clinical progress

See more
content on

Nykode Therapeutics

Ocugen (OCGN)

Latest price

USD1.23

▾ 0.02 (1.65)

As at 10/12/2025

Market capitalisation: USD378m

View equity

Quickview

Healthcare

14.08.25

Ocugen — Novel cell therapies for retinal diseases

See more
content on

Ocugen

Okyo Pharma (OKYO)

Latest price

USD2.02

▾ 0.05 (2.54)

As at 10/12/2025

Market capitalisation: USD75m

View equity

Quickview

Healthcare

06.05.25

Okyo Pharma — Targeting underserved corneal diseases

See more
content on

Okyo Pharma

Oncopeptides (ONCO)

Latest price

SEK5.31

▾ −0.11 (−2.03)

As at 10/12/2025

Market capitalisation: SEK1,402m

View equity

Quickview

Healthcare

27.08.25

Oncopeptides — Targeted oncology with commercial momentum

See more
content on

Oncopeptides

OpGen (OPGN)

Latest price

—

— 0.00 (0.00)

As at 10/12/2025

Market capitalisation: —

View equity

Quickview

TMT

25.07.25

Reach — Clarifying the narrative

Quickview

TMT

10.03.25

Informa — FY25–28 plan for leveraging B2B platform

Quickview

Financials

06.03.25

Lancashire Holdings — Substantial shareholder distributions

See more
content on

OpGen

Oryzon Genomics (ORY)

Latest price

EUR3.17

▾ −0.13 (−3.95)

As at 10/12/2025

Market capitalisation: EUR264m

View equity

Flash

Healthcare

09.12.25

Oryzon Genomics — ASH 2025: Promising iadademstat updates

Update

Healthcare

11.11.25

Oryzon Genomics — Progression across the pipeline in Q3

Flash

Healthcare

04.11.25

Oryzon Genomics — Progress for iadademstat across the board

See more
content on

Oryzon Genomics

OSE Immunotherapeutics (OSE)

Latest price

EUR5.01

▾ 0.23 (4.81)

As at 10/12/2025

Market capitalisation: EUR108m

View equity

Flash

Healthcare

09.12.25

OSE Immunotherapeutics — Strategic plan presented for 2026–2028

Quickview

Industrials

10.11.25

International Airlines Group — Compounding a strong Q324 comparative

Flash

Healthcare

20.10.25

OSE Immunotherapeutics — Refocusing for the next phase

See more
content on

OSE Immunotherapeutics

Percheron Therapeutics (PER)

Latest price

AUD0.01

— 0.00 (−12.50)

As at 10/12/2025

Market capitalisation: AUD9m

View equity

Update

Healthcare

27.11.25

Percheron Therapeutics — Phase II visibility drives valuation upgrade

Flash

Healthcare

07.10.25

Percheron Therapeutics — Positive Phase I readout strengthens outlook

Initiation

Healthcare

17.09.25

Percheron Therapeutics — Resetting the narrative with a VISTA focus

See more
content on

Percheron Therapeutics

Curated by Edison

singularityhub.com

The Next Step for AI in Biology Is to Predict How Proteins Behave in the Body

Healthcare

A new protein atlas can help turn static AI predictions of protein shapes into more fluid predictions of how proteins behave in the body.

Read article

www.genome.gov

The Cost of Sequencing a Human Genome

Healthcare

Estimated cost of sequencing the human genome over time since the Human Genome Project.

Read article

www.prnewswire.com

J.P. Morgan Launches New Life Sciences Private Capital Team Targeting Investments in Innovative Healthcare Companies

Healthcare

/PRNewswire/ -- J.P. Morgan Asset Management today announced the launch of a new life sciences private equity team, Life Sciences Private Capital. The new team...

Read article

insights.omnia-health.com

Leveraging nanotechnology to transform the disinfection industry

Healthcare

Co-founders of Kismet Technologies, Christina Drake and Shari Costantini, discuss how NanoRad, one of their flagship products, uses targeted application to kill a wide range of bacteria and viruses.

Read article

www.bain.com

2022 Healthcare Provider IT Report: Post-Pandemic Investment Priorities

Healthcare

As healthcare providers enter a new period of disruption, their software investment priorities present opportunities for vendors and investors.

Read article

Thematics

thematic

Healthcare

06.01.23

Outlook for 2023: Biotechs remain central to novel drug development

thematic

Healthcare

04.01.23

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

thematic

Healthcare

20.12.22

Cell and gene therapies

thematic

Healthcare

28.11.22

Drug delivery platforms

thematic

Healthcare

07.11.22

Oncology ABCs (part three) – thinking outside the box in women’s cancer

thematic

Healthcare

01.11.22

Neuroscience comeback

thematic

Consumer

05.10.22

IPO apocalypse

thematic

Healthcare

03.10.22

Oncology ABCs (part two) – vaccines: niche no longer

Equities

Equities by Sector

Sectors

Thematics

Latest

Edison explains: AI slop – when fake news costs real money

Digital assets – Part 5: Digital asset treasury companies

Edison explains: UK Budget – Why the market rallied despite the tax grab

Audiovisual

Latest

Topps Tiles – executive interview

BlackRock Greater Europe Investment Trust – equity proposition

Ovanti – executive interview

About Edison

About Edison

Careers

Healthcare

Immix Biopharma

1.97%

Healthcare Insights

Healthcare-focused trusts: A sector on the mend

The CNS renaissance: Innovations are reshaping neurological therapies

Edison explains: Investing in health stocks – how policy clarity is opening doors

Latest

Mendus — ASH 2025 update supports renewed strategy

OSE Immunotherapeutics — Strategic plan presented for 2026–2028

Immix Biopharma — Promising NEXICART-2 data; runway extended

Oryzon Genomics — ASH 2025: Promising iadademstat updates

An update on OpGen: Deals, expansion and revenues

Volition: Views from the sharp end

Incannex Healthcare: Data opens path to treat anxiety

February 2023 Edition of Edison Healthcare Insight

VolitionRx: Commercializing the Nu.Q Vet Cancer Test: Webinar

Encouraging top-line data from Unyvero urinary tract infection (UTI) panel

Equities

Immix Biopharma (IMMX)

USD6.73

Immix Biopharma — Promising NEXICART-2 data; runway extended

Immix Biopharma — Primed to pick up the pace in ALA

Immix Biopharma — NEXICART-2 enrolment progressing well

See morecontent on

IRLAB Therapeutics (IRLAB-A)

SEK1.98

IRLAB Therapeutics — Next steps laid out for IRL757

IRLAB Therapeutics — Pirepemat stumbles in Phase IIb study

IRLAB Therapeutics — EMA alignment on mesdopetam Phase III plans

See morecontent on

KALA BIO (KALA)

USD0.77

LTR Pharma (LTP)

AUD0.48

LTR Pharma — Sizable upside potential for intranasal delivery

See morecontent on

Medigene (MDG1)

EUR0.13

Mendus (IMMU)

SEK5.00

Mendus — ASH 2025 update supports renewed strategy

Mendus — Ovarian cancer: another shot at goal

Mendus — New strategy broadens vididencel potential

See morecontent on

MindMaze Therapeutics (RLF)

CHF2.81

Newron Pharmaceuticals (NWRN)

CHF19.88

Newron Pharmaceuticals — Phase III ENIGMA-TRS 2 trial underway

Newron Pharmaceuticals — H125 results reflect evenamide progress

Newron Pharmaceuticals — ENIGMA-TRS 1 commences enrolment

See morecontent on

Nykode Therapeutics (NYKD)

NOK2.43

Nykode Therapeutics — Repositioned to streamline clinical progress

See morecontent on

Ocugen (OCGN)

USD1.23

Ocugen — Novel cell therapies for retinal diseases

See morecontent on

Okyo Pharma (OKYO)

USD2.02

Okyo Pharma — Targeting underserved corneal diseases

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on